EUVIMEDEUVIMED entdecken
Crossref

Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab

Tomomitsu Matono, Toshifumi Tada iD, Takashi Kumada iD, Atsushi Hiraoka iD, Masashi Hirooka iD, Kazuya Kariyama iD, Joji Tani iD, Masanori Atsukawa iD, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi iD, Hiroki Nishikawa iD und 39 weitere

Hepatology Research · 2025-09 · 55 (9) · 1285-1295

DOI: 10.1111/hepr.14224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 14.06.2025. Verfasst von Tomomitsu Matono und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the prognostic impact of the neutrophil‐to‐lymphocyte ratio (NLR) on outcomes in patients with hepatocellular carcinoma (HCC) treated with durvalumab plus tremelimumab (Dur/Tre).

Methods

A total of 182 patients with HCC who received Dur/Tre were included in the analysis. Univariate and multivariate survival analyses were conducted. Additionally, hazard ratio (HR) spline curve analysis was used to determine the optimal NLR cut‐off values for predicting overall survival (OS).

Results

The median progression‐free survival (PFS) was 3.5 months (95% confidence interval [CI]: 2.7–4.4), whereas the median OS was not reached (95% CI: 12.1 months–not reached). Multivariate analysis demonstrated that treatment with Dur/Tre as a second‐line therapy or beyond was independently associated with worse PFS (HR: 1.819; 95% CI: 1.230–2.688; p = 0.003). Furthermore, an NLR of ≥ 2.56 was identified as an independent predictor of reduced OS (HR: 1.919; 95% CI: 1.033–3.566; p = 0.039). The median OS was not reached (95% CI: 12.3 months–not reached) in patients with an NLR of < 2.56, compared with 12.1 months (95% CI: 9.0 months–not reached) in those with an NLR of ≥ 2.56 ( p = 0.016). A Sankey diagram illustrating post‐treatment outcomes revealed that a significantly larger proportion of patients with high NLRs did not proceed to subsequent therapies but instead received best supportive care ( p = 0.046). Spline curve analysis showed that an NLR range of approximately 2.3–3.0 represents an appropriate cut‐off for predicting OS.

Conclusions

The NLR is a significant prognostic biomarker for OS in patients with HCC treated with Dur/Tre.

Schlagwörter

Stichwörter der Autor:innen

durvalumabhepatocellular carcinomaneutrophil‐to‐lymphocyte ratiooverall survivaltremelimumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Hyogo Prefectural Harima-Himeji General Medical Center, Himeji, Japan.
  • Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
  • Department of Nursing, Gifu Kyoritsu University, Gifu, Japan.
  • Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan.
  • Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.

ORCID-Profile: Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Taeang Arai, Takashi Nishimura, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Osamu Yoshida, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo

Zitieren

APA

Matono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Nishikawa, H., Tanaka, K., Tsuji, K., Ishikawa, T., Tajiri, K., Koshiyama, Y., Toyoda, H., Ogawa, C., …, & Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group (2025). Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Hepatology Research, 55(9), 1285-1295. https://doi.org/10.1111/hepr.14224

Vancouver

Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al. Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab. Hepatology Research. 2025;55(9):1285-1295. doi:10.1111/hepr.14224

BibTeX
@article{Matono2025,
  author = {Matono, Tomomitsu and Tada, Toshifumi and Kumada, Takashi and Hiraoka, Atsushi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Fukunishi, Shinya and Nishikawa, Hiroki and Tanaka, Kazunari and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Koshiyama, Yuichi and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Ohama, Hideko and Tada, Fujimasa and Nouso, Kazuhiro and Morishita, Asahiro and Tsutsui, Akemi and Nagano, Takuya and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Nishimura, Takashi and Imai, Michitaka and Kosaka, Hisashi and Naganuma, Atsushi and Aoki, Tomoko and Kuroda, Hidekatsu and Yata, Yutaka and Tamai, Hideyuki and Matsuura, Takanori and Komatsu, Shohei and Ueda, Yoshihide and Nakamura, Yoshiko and Yoshida, Osamu and Nakamura, Shinichiro and Enomoto, Hirayuki and Kaibori, Masaki and Fukumoto, Takumi and Hiasa, Yoichi and Kudo, Masatoshi and Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group, Real‐life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group},
  title = {Neutrophil–Lymphocyte Ratio Predicts Overall Survival in Patients With HCC Treated With Durvalumab Plus Tremelimumab},
  journal = {Hepatology Research},
  year = {2025},
  volume = {55},
  number = {9},
  pages = {1285--1295},
  doi = {10.1111/hepr.14224}
}
Kostenlos starten →